COMPANY PROFILE / #1918
Fathom Therapeutics
New York, NYVenture Capital-Backed
OVERVIEW
Developer of a computational molecular design system intended for drug discovery and therapeutic development. The company's platform combines physics-based simulations, machine learning models, and high-performance computing to generate and evaluate molecular designs, simulate protein-protein interactions, predict binding affinities, and optimize therapeutic degraders, enabling pharmaceutical researchers and biotech companies to identify novel drug candidates, accelerate discovery timelines, and reduce development costs for previously intractable biological targets.
已融资54.08
最新估值120.00
员工数7
成立年份2023
公司概况
- Companies
- Fathom Therapeutics
- Description
- Developer of a computational molecular design system intended for drug discovery and therapeutic development. The company's platform combines physics-based simulations, machine learning models, and high-performance computing to generate and evaluate molecular designs, simulate protein-protein interactions, predict binding affinities, and optimize therapeutic degraders, enabling pharmaceutical researchers and biotech companies to identify novel drug candidates, accelerate discovery timelines, and reduce development costs for previously intractable biological targets.
- Website
- www.fathomtx.com
- HQ Location
- New York, NY
- Year Founded
- 2023
- Keywords
- drug candidates discovery, drug candidates testing, medicine discovery, protein discovery, protein research, protein study
- Competitors
- —
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 54.08
- First Financing Date
- 15-Nov-2023
- First Financing Size
- 7.08
- First Financing Valuation
- 33.00
- Last Financing Date
- 27-Apr-2026
- Last Financing Deal Type
- Early Stage VC
- Last Financing Size
- 47.00
- Last Financing Valuation
- 120.00
- Last Financing Status
- Completed
- Last Known Valuation
- 120.00
- Last Known Valuation Date
- 27-Apr-2026
- Last Known Valuation Deal Type
- Early Stage VC
- Valuation Estimate
- 153.66
- Valuation Estimate Growth Rate
- 28.05%
- Active Investors
- 8VC, Alexandria Venture Investments, Chemistry Ventures, JAZZ Venture Partners, New Leaf Venture, New York Venture Partners, Prime Movers Lab, Sutter Hill Ventures
- # Active Investors
- 8
- Acquirers
- —
团队与联系人
- Employees
- 7
- Employee Growth %
- —
- Employee History
- 2024: 7
- Primary Contact
- Huafeng Xu
- Primary Contact Title
- Co-Founder, Chief Executive Officer & Board Member
- Primary Contact Email
- huafeng@atommap.com
- Primary Contact Phone
- +1 (917) 968-8176
增长与经营
- Revenue
- —
- Revenue Growth %
- —
- Growth Rate
- 0.00%
- Growth Rate % Change
- —
- Growth Rate Percentile
- 13
- Size Multiple
- 3.46x
- Size Multiple % Change
- —
- Size Multiple Change
- —
- Size Multiple Percentile
- 76
- Majestic Referring Domains
- 90
- SimilarWeb Unique Visitors
- —
- SimilarWeb Unique Visitors Change
- —
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 10%
- Success Probability Over Time – 3 Year
- 25%
- Success Probability Over Time – 5 Year
- 37%
记录来源:public.companies · 原始序号 #1918 · 所有字段均按数据库原值展示。